证券研究报告 | 公司深度 | 多元金融 国网英大(600517) 报告日期：2025 年 05 月 27 日 "金融+制造"双主业驱动，有望受益电网投资加速 ——国网英大深度报告 qiushiliang@stocke.com.cn 分析师：刘巍 执业证书号：S1230524040001 liuwei03@stocke.com.cn 投资要点 ❑ 国家电网下属子公司，增资扩股布局多元金融 公司是国网英大国际控股集团子公司，同时也是国家电网孙公司。公司前身为上 海置信电气股份有限公司，2020年 2月完成重大资产重组，注入信托、证券、期 货等金融业务。2024年，公司实现营业收入 112.88亿元，同比增长 3.60%，归属 于上市公司股东的净利润 15.74 亿元，同比增长 15.39%。2024年，英大信托、英 大证券、英大碳资产、置信电气净利润分别为 17.8、1.8、0.1、1.5 亿元。 ❑ 碳资产：碳市场运行框架逐步建立，公司碳资产业务有望持续高增 "十四五"是碳达峰的关键期和窗口期，随着碳市场建设顶层设计加速完善，市场 交易量价齐升。英大碳资产成立于 2013 年 11 月，2021 年 1 月划 ...

证券研究报告 | 公司深度 | 多元金融 国网英大(600517) 报告日期：2025 年 05 月 27 日 "金融+制造"双主业驱动，有望受益电网投资加速 ——国网英大深度报告 投资要点 ❑ 国家电网下属子公司，增资扩股布局多元金融 公司是国网英大国际控股集团子公司，同时也是国家电网孙公司。公司前身为上 海置信电气股份有限公司，2020年 2月完成重大资产重组，注入信托、证券、期 货等金融业务。2024年，公司实现营业收入 112.88亿元，同比增长 3.60%，归属 于上市公司股东的净利润 15.74 亿元，同比增长 15.39%。2024年，英大信托、英 大证券、英大碳资产、置信电气净利润分别为 17.8、1.8、0.1、1.5 亿元。 ❑ 碳资产：碳市场运行框架逐步建立，公司碳资产业务有望持续高增 "十四五"是碳达峰的关键期和窗口期，随着碳市场建设顶层设计加速完善，市场 交易量价齐升。英大碳资产成立于 2013 年 11 月，2021 年 1 月划归英大股份直接 管理，是国网公司系统内唯一的专业碳资产管理公司。公司基本业务做优夯实， 持续培育新兴业务。2024 年英大碳资产实现营业收入 0.70 亿 ...

Investment Rating - The report maintains a "Buy" rating for the company [3] Core Insights - The company slightly exceeded profit expectations in Q1 2025, with revenue reaching 138.30 billion, a year-on-year increase of 16.2%, and operating profit (Non-GAAP) at 40.43 billion, up 7.4% year-on-year [6] - The company is expected to achieve revenue of 624.84 billion, 705.27 billion, and 793.32 billion for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 17.24%, 12.87%, and 12.48% [2] - The company is expanding its overseas investments, which has led to a slight decline in profit margins, with a gross margin of 80.4% in Q1 2025, down 0.8 percentage points year-on-year [6] - The international OTA platform bookings grew over 60% year-on-year, and inbound tourism increased by over 100% [6] - The company is accelerating its AI strategy, which is expected to enhance customer service efficiency significantly [6] Financial Summary - The projected net profit for the company is 169.59 billion, 199.39 billion, and 226.82 billion for 2025, 2026, and 2027 respectively, with a year-on-year change of -0.63%, +17.57%, and +13.75% [2] - The earnings per share (EPS) are forecasted to be 23.77, 27.94, and 31.79 for 2025, 2026, and 2027 respectively [2] - The company’s total assets are expected to reach 275.05 billion, 297.69 billion, and 329.00 billion for 2025, 2026, and 2027 respectively [7]

Investment Rating - The report maintains a "Buy" rating for the company [3] Core Views - The company's Q1 2025 profit slightly exceeded expectations, with revenue reaching 138.30 billion, a year-on-year increase of 16.2%, and operating profit (Non-GAAP) at 40.43 billion, up 7.4% year-on-year [6] - The company is expected to achieve revenue of 624.84 billion, 705.27 billion, and 793.32 billion for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 17.24%, 12.87%, and 12.48% [2] - The company is expanding its overseas investments, contributing to revenue growth, with international OTA platform bookings increasing over 60% year-on-year [6] - The company is accelerating its AI strategy, which is expected to enhance customer service efficiency significantly [6] Financial Summary - The forecasted revenue and net profit for the company from 2025 to 2027 are as follows: - Revenue: 624.84 billion (2025), 705.27 billion (2026), 793.32 billion (2027) - Net Profit: 169.59 billion (2025), 199.39 billion (2026), 226.82 billion (2027) [2][7] - The company's earnings per share (EPS) is projected to be 23.77 yuan in 2025, 27.94 yuan in 2026, and 31.79 yuan in 2027 [2][7] - The price-to-earnings (P/E) ratio is expected to be 19X in 2025, 16X in 2026, and 14X in 2027 [2]

证券研究报告 | 浙商早知道 报告日期：2025 年 05 月 27 日 浙商早知道 2025 年 05 月 27 日 ：王禾 执业证书编号：S1230512110001 ：021-80105901 http://www.stocke.com.cn 1/3 请务必阅读正文之后的免责条款部分 大势：5 月 26 日上证指数下跌 0.05%，沪深 300 下跌 0.57%，科创 50 上涨 0.17%，中证 1000 上涨 0.65%，创业板 指下跌 0.8%，恒生指数下跌 1.35%。 行业：5 月 26 日表现最好的行业分别是传媒（+2.14%)、计算机（+1.39%)、环保（+1.22%)、通信（+1.1%)、轻工 制造（+1.04%)，表现最差的行业分别是汽车（-1.78%)、医药生物（-1.08%)、综合（-0.86%)、银行（-0.75%)、家 用电器（-0.71%)。 资金：5 月 26 日全 A 总成交额为 10339 亿元，南下资金净流出 15.07 亿港元。 浙商早报 1 市场总览 ：wanghe@stocke.com.cn 市场总览 重要观点 【浙商宏观 李超/林成炜/廖博/潘高远/费瑾】宏 ...

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [7] Core Views - The company is expected to achieve revenue growth driven by new product launches, international expansion, and innovation in drug development. The anesthetic pipeline continues to evolve, with several high-barrier products approved for market entry, which is anticipated to enhance the company's competitive edge in the anesthetic and analgesic sectors [10][12] Summary by Relevant Sections Growth Capability - In 2024, the company's chemical preparations generated revenue of 1.077 billion yuan, a year-over-year increase of 22.25%. Chemical raw materials achieved revenue of 121 million yuan, up 28.65%. CMO/CDMO services saw revenue of 65 million yuan, a significant increase of 111.59%. The company has undertaken 23 CMO/CDMO projects, indicating strong growth potential from new product launches and international business expansion [2] - The company plans to launch at least 10 generic drug products and submit at least 10 new product applications in 2025, which is expected to contribute to revenue growth in the coming years [2] Internationalization of Formulations - The company received FDA approval for its Nicardipine Hydrochloride Injection in September 2024, marking its first shipment to the U.S. market. The company is gradually expanding its international product offerings, with several ANDA applications submitted for various products [3] Competitive Position in Anesthesia - As of 2024, the company has launched 16 products in the anesthetic and analgesic fields, with over 20 in development. The market share for key products is strong, with the company's Nalmefene Hydrochloride Injection holding a 61.73% market share. Newly approved high-barrier products are expected to drive revenue growth [4] - The company is advancing its high-end generic drugs, improved new drugs, and innovative drugs in the anesthetic and analgesic sectors, which will help establish its brand and enhance core competitiveness [4] Innovation and R&D Acceleration - The company is accelerating its transition from generic to innovative drug development, with R&D expenditures exceeding 20% of revenue in 2024. Investment in innovative drugs accounts for nearly 30% of R&D spending, indicating a strong commitment to innovation [5] Financial Performance - In 2024, the company achieved revenue of 1.35 billion yuan, a year-over-year increase of 20.82%, with a net profit of 238 million yuan, up 5.15%. The net profit margin after excluding stock incentive expenses showed a stable growth trend [10][12] - The overall gross margin for 2024 was 74.93%, a decrease of 5.08 percentage points, primarily due to declines in the gross margins of technical services, CMO/CDMO, and raw materials [11] Earnings Forecast and Valuation - The company is projected to achieve EPS of 1.56, 1.83, and 2.19 yuan per share for 2025, 2026, and 2027, respectively. The current closing price corresponds to a PE ratio of 22 times for 2025 [12]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Viewpoints - The company is expected to see a turning point in its domestic business in 2025 due to the anticipated recovery in local special bonds and monthly bidding for various medical devices. The international market is projected to grow significantly, driven by the company's high-end customer base and balanced revenue distribution across major regions, particularly in developing countries and Europe [1][2] - The company’s revenue from the life information and support segment decreased by 11.1% in 2024, while the minimally invasive surgery business grew over 30%. The international life information and support business achieved double-digit growth [2] - The in-vitro diagnostics segment saw a revenue increase of 10.8% in 2024, with international business growing over 30%. The company ranked third in the domestic market for chemiluminescence and surpassed 15% market share in biochemical business [3] - The medical imaging segment's revenue grew by 6.6% in 2024, with international business growing over 15%. The high-end ultrasound system Resona A20 generated over 400 million yuan in its first year [3] - The company's gross margin was 63.1% in 2024, a decrease of 3.0 percentage points year-on-year, while the net profit margin was 32.0%, down 1.2 percentage points [4] - The company is expected to maintain stable growth from 2025 to 2027, driven by the global medical infrastructure wave and expansion in high-end markets [5] Financial Summary - The company's revenue for 2024 is projected at 36,726 million yuan, with a year-on-year growth of 5.14%. By 2027, revenue is expected to reach 52,497 million yuan, reflecting a growth rate of 14.72% [12] - The net profit attributable to the parent company for 2024 is estimated at 11,668 million yuan, with a slight increase of 0.74% year-on-year. By 2027, it is projected to reach 16,943 million yuan, growing at 15.53% [12] - The earnings per share (EPS) for 2024 is expected to be 9.62 yuan, increasing to 13.97 yuan by 2027 [12]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company is expected to see a turning point in its domestic business in 2025 due to the anticipated recovery in local special bonds and monthly bidding for various medical devices, despite short-term impacts from tight local finances and delays in regular tenders [1] - The international market is projected to grow significantly, driven by the company's continued penetration into high-end customer segments and balanced revenue distribution across major global regions, particularly in developing countries and Europe [1] - The company is expected to maintain steady long-term growth, supported by the global medical infrastructure wave and expansion into high-end markets [5] Business Segmentation and Highlights - **Life Information and Support Segment**: Revenue decreased by 11.1% in 2024, with minimally invasive surgery business growing over 30%. Internationally, this segment achieved double-digit growth [2] - **In Vitro Diagnostics Segment**: Revenue grew by 10.8% in 2024, surpassing the Life Information and Support segment for the first time. Internationally, this segment saw growth exceeding 30% [3] - **Medical Imaging Segment**: Revenue increased by 6.6% in 2024, with international business growing over 15%. The high-end ultrasound system Resona A20 generated over 400 million yuan in its first year [3] Profitability Analysis - The company's gross margin for 2024 was 63.1%, a decrease of 3.0 percentage points year-on-year, while the net profit margin was 32.0%, down 1.2 percentage points [4] - Operating cash flow for 2024 was 12.43 billion yuan, a year-on-year increase of 12.4%, representing 102.8% of net operating income [4] - Profitability is expected to improve slightly from 2025 to 2027, driven by an increase in high-end product sales and stable operating expense ratios [4] Financial Forecast and Valuation - The company is projected to maintain stable growth from 2025 to 2027, with expected revenues of 40.33 billion yuan in 2025, 45.76 billion yuan in 2026, and 52.50 billion yuan in 2027, reflecting growth rates of 9.82%, 13.46%, and 14.72% respectively [12] - The estimated earnings per share (EPS) for 2025 is 10.61 yuan, with a price-to-earnings (P/E) ratio of 21.86 [10][12]

证券研究报告 金属大典（2025年版） 行业评级：看好 2025年5月26日 n 邮箱 shenhaojun@stocke.com.c 证书编号 S1230523080011 证书编号 S1230523100001 邮箱 wangnanqing@stocke.com.cn 分析师 沈皓俊 分析师 王南清 研究助理 何玉静 沈家悦 张轩 01 铜业弹性表 | 添加标题 | | --- | 资料来源：公司年报，公司公告，公司公众号，浙商证券研究所。注： 2 2025-2027年产量数据为预测值，存在预测偏差风险。江西铜业 统计公司自有矿数据；云南铜业统计并表产量口径；金诚信2024-2026年产量中未统计Lubambe铜矿（因公告矿山处于技改阶段）。 电解铝股弹性表（2025年5月） 02 我们梳理了电解铝企业2025年产量弹性以及利润弹性： （1）从吨铝市值来看：目前云铝/宏桥最低，约为21000元/吨，中铝次之，电解铝资产较纯粹，资产价值亟待重估。 （2）从PE来看：由于产能基本固定，盈利能力成为电解铝公司比拼的核心要点，目前宏桥港股/神火/中铝港股PE 偏低。2025年氧化铝价格波动性走低，带动云铝/神火/ ...

证券研究报告 钢铁周报：铁水顶部信号明显，但行业基本面仍健康 行业评级：看好 2025 年 05 月 26 日 | 分析师 | 沈皓俊 | 研究助理 | 张轩 | | --- | --- | --- | --- | | 邮箱 | shenhaojun@stocke.com.cn | 邮箱 | zhangxuan01@stocke.com.cn | | 证书编号 | S1230523080011 | | | 价格 | | 【浙商金属 沈皓俊】 | | 钢铁周度数据 | | | （2025年5月25日） | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 价格 | | | | 周涨跌幅 | | 年初至今涨跌幅 | | | | 上证指数 | | 3 , | 348 | -0 . | 6% | -0 . | 1% | | | 沪深300 | | 3 , | 882 | -0 . | 2% | -1 . | 3% | | 板 | SW钢铁指数 | | 2 , | 139 | -0 . | 9% | 1 . | 8% | | 块 | | SW ...